Skip to main
HUM
HUM logo

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 37 analyst ratings
Buy
Strong Buy 19%
Buy 27%
Hold 51%
Sell 3%
Strong Sell 0%

Bulls say

Humana has demonstrated stable cost trends and is poised for significant improvement in adjusted earnings per share, particularly if it successfully appeals for star ratings, which could elevate contracts into bonus-eligible territory. The company is anticipated to achieve stronger revenue than consensus estimates in the near term, driven by strategic pricing actions and an emphasis on improving Medicare Advantage margins, despite some elevated medical costs. Additionally, Humana's investments in clinical excellence and favorable industry positioning through its high Medicare Advantage Star Ratings further strengthen its competitive advantage amidst ongoing regulatory changes.

Bears say

Humana's stock faces a negative outlook primarily due to a "Stars miss," which has led to increased margin pressure amidst rising utilization trends. The company is projected to experience stagnant earnings per share (EPS) and medical loss ratio (MLR) year-over-year in 2025, raising concerns about its ability to achieve target margins by the previously anticipated timeline of 2027. Additionally, ongoing investments to enhance clinical excellence are expected to further postpone financial recovery, with projections suggesting a more realistic timeline for margin improvement might extend to 2028.

Humana (HUM) has been analyzed by 37 analysts, with a consensus rating of Buy. 19% of analysts recommend a Strong Buy, 27% recommend Buy, 51% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Buy based on their latest research and market trends.

According to 37 analysts, Humana (HUM) has a Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $317.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $317.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.